A new glycoengineered form of anti-CD20 monoclonal antibody in treatment of multiple sclerosis
Therapeutic Advances in Neurological Disorders
Published online on March 30, 2026
Abstract
Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
B-cell depletion with anti-CD20 monoclonal antibody (mAb) represents a novel and highly effective treatment for patients with multiple sclerosis. Although all approved anti-CD-20 mAbs for multiple sclerosis (MS) treatment, ocrelizumab, ofatumumab, and ...
B-cell depletion with anti-CD20 monoclonal antibody (mAb) represents a novel and highly effective treatment for patients with multiple sclerosis. Although all approved anti-CD-20 mAbs for multiple sclerosis (MS) treatment, ocrelizumab, ofatumumab, and ...